Provided by Tiger Fintech (Singapore) Pte. Ltd.

INmune Bio Inc

8.12
-0.0200-0.25%
Post-market: 8.07-0.0465-0.57%18:07 EDT
Volume:218.49K
Turnover:1.76M
Market Cap:180.04M
PE:-3.72
High:8.18
Open:8.00
Low:7.89
Close:8.14
Loading ...

Inmune Bio (INMB) Receives a Buy from Scotiabank

TIPRANKS
·
05 Mar

Is INmune Bio (NASDAQ:INMB) A Risky Investment?

Simply Wall St.
·
27 Feb

INmune Bio Is Maintained at Buy by Maxim Group

Dow Jones
·
14 Feb

INmune Bio Opens Phase Ii in High Dose Cohort of Inkmune™ Trial in Prostate Cancer

THOMSON REUTERS
·
12 Feb

INmune Bio Inc - Phase 1 Cohorts Show No Safety Issues

THOMSON REUTERS
·
12 Feb

INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer

GlobeNewswire
·
12 Feb

INmune Bio Is Maintained at Sector Outperform by Scotiabank

Dow Jones
·
11 Feb

INmune Bio price target raised to $23 from $22 at Scotiabank

TIPRANKS
·
11 Feb

Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), Inmune Bio (INMB) and Vertex Pharmaceuticals (VRTX)

TIPRANKS
·
11 Feb

Scotiabank Sticks to Its Buy Rating for Inmune Bio (INMB)

TIPRANKS
·
11 Feb

INmune Bio to Seek Approval of Skin Disorder Treatment in US, UK, Europe

MT Newswires Live
·
10 Feb

INmune Bio Inc - to Seek Marketing Authorizations in EU and UK for Cordstrom

THOMSON REUTERS
·
10 Feb

INmune Bio Announces Plan to Submit FDA Biologics License Application (Bla) Seeking Approval of Cordstrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (Rdeb)

THOMSON REUTERS
·
10 Feb

INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

GlobeNewswire
·
10 Feb

INmune Bio Inc. Expands Inkmune Trial in Prostate Cancer to Veterans

THOMSON REUTERS
·
28 Jan

INmune Bio Inc. Expands INKmune Trial in Prostate Cancer to Veterans

GlobeNewswire
·
28 Jan